UNCY vs. OCUP, XLO, APLM, LEXX, PMN, CARA, MRKR, IMRX, BOLT, and EYEN
Should you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Ocuphire Pharma (OCUP), Xilio Therapeutics (XLO), Apollomics (APLM), Lexaria Bioscience (LEXX), ProMIS Neurosciences (PMN), Cara Therapeutics (CARA), Marker Therapeutics (MRKR), Immuneering (IMRX), Bolt Biotherapeutics (BOLT), and Eyenovia (EYEN). These companies are all part of the "pharmaceutical preparations" industry.
Ocuphire Pharma (NASDAQ:OCUP) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk, institutional ownership and community ranking.
In the previous week, Ocuphire Pharma had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 3 mentions for Ocuphire Pharma and 1 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.22 beat Ocuphire Pharma's score of 0.00 indicating that Ocuphire Pharma is being referred to more favorably in the media.
Ocuphire Pharma has higher revenue and earnings than Unicycive Therapeutics. Ocuphire Pharma is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
15.0% of Ocuphire Pharma shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 8.7% of Ocuphire Pharma shares are owned by company insiders. Comparatively, 42.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Unicycive Therapeutics has a net margin of 0.00% compared to Unicycive Therapeutics' net margin of -52.42%. Ocuphire Pharma's return on equity of 0.00% beat Unicycive Therapeutics' return on equity.
Ocuphire Pharma has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.72, meaning that its stock price is 172% more volatile than the S&P 500.
Ocuphire Pharma presently has a consensus target price of $19.00, suggesting a potential upside of 938.25%. Unicycive Therapeutics has a consensus target price of $5.30, suggesting a potential upside of 369.03%. Given Unicycive Therapeutics' higher possible upside, analysts clearly believe Ocuphire Pharma is more favorable than Unicycive Therapeutics.
Ocuphire Pharma received 13 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. Likewise, 65.96% of users gave Ocuphire Pharma an outperform vote while only 64.29% of users gave Unicycive Therapeutics an outperform vote.
Summary
Ocuphire Pharma beats Unicycive Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Unicycive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Unicycive Therapeutics Competitors List
Related Companies and Tools
